Of note, add-on metformin to neo-adjuvant treatment of ErbB2 breast cancer in non-diabetic patients has recently been reported to fail in improving pathologic complete response [54], indicating perhaps metformin limitation in the non-diabetic breast cancer context. Here, ERBB2 is linked to breast carcinoma.